ticlopidine has been researched along with Dyslipidemias in 3 studies
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.
Dyslipidemias: Abnormalities in the serum levels of LIPIDS, including overproduction or deficiency. Abnormal serum lipid profiles may include high total CHOLESTEROL, high TRIGLYCERIDES, low HIGH DENSITY LIPOPROTEIN CHOLESTEROL, and elevated LOW DENSITY LIPOPROTEIN CHOLESTEROL.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| De Kam, PJ | 1 |
| Luo, WL | 1 |
| Wenning, L | 1 |
| Ratcliffe, L | 1 |
| Sisk, CM | 1 |
| Royalty, J | 1 |
| Radziszewski, W | 1 |
| Wagner, JA | 1 |
| Lai, E | 1 |
| Hagström, E | 1 |
| Roe, MT | 1 |
| Hafley, G | 1 |
| Neely, ML | 1 |
| Sidhu, MS | 1 |
| Winters, KJ | 1 |
| Prabhakaran, D | 1 |
| White, HD | 1 |
| Armstrong, PW | 1 |
| Fox, KA | 1 |
| Ohman, EM | 1 |
| Boden, WE | 1 |
| Liao, JK | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Study to Evaluate the Effects of Laropiprant on the Antiplatelet Effects of Clopidogrel and Aspirin in Combination and to Evaluate Single Dose Pharmacokinetics of MK0524A in Subjects With Primary Hypercholesterolemia or Mixed Dyslipidemia[NCT01012219] | Phase 1 | 36 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Cutaneous bleeding Time (BT) on Day 8 after daily administration of laropiprant with aspirin and clopidogrel for 7 days versus BT on Day 8 after daily administration of placebo with aspirin and clopidogrel for 7 days.~The model used included treatment, period and sequence as fixed effect variables and subjects as the random effect variable.~Period 3 was not analyzed as bleeding time was not an objective for this part of the study." (NCT01012219)
Timeframe: Day 8
| Intervention | Seconds (Least Squares Mean) |
|---|---|
| Clopidogrel + Aspirin +Laropiprant | 478 |
| Clopidogrel + Aspirin | 389 |
1 review available for ticlopidine and Dyslipidemias
| Article | Year |
|---|---|
Secondary prevention of stroke and transient ischemic attack: is more platelet inhibition the answer?
Topics: Aspirin; Atherosclerosis; Cilostazol; Clinical Trials as Topic; Clopidogrel; Coronary Disease; Dipyr | 2007 |
2 trials available for ticlopidine and Dyslipidemias
| Article | Year |
|---|---|
The effects of laropiprant on the antiplatelet activity of co-administered clopidogrel and aspirin.
Topics: Adult; Aged; Aspirin; Clopidogrel; Cross-Over Studies; Double-Blind Method; Drug Interactions; Dysli | 2014 |
Association Between Very Low Levels of High-Density Lipoprotein Cholesterol and Long-term Outcomes of Patients With Acute Coronary Syndrome Treated Without Revascularization: Insights From the TRILOGY ACS Trial.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Biomarkers; Cholesterol, HDL; Clopidogrel; | 2016 |